Trial reportThe British journal of radiology2015
LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective.
Trial report in The British journal of radiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary Oligometastases: a Prospective, Randomized, Controlled Phase II Study
Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Centrally Located Early-stage Non-small Cell Lung Cancer: a Prospective, Single-arm, Phase II Study
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer.The British journal of radiology · 2017Pooled it
- Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2017Trial
- Lungtech, a phase II EORTC trial of SBRT for centrally located lung tumours - a clinical physics perspective.Radiation oncology (London, England) · 2016Trial
- Outcome and safety of SBRT in centrally and ultra-centrally located lung tumours: A PRISMA-based systematic review and Meta-Analysis.Clinical and translational radiation oncology · 2026Article
- A review of clinical trial radiotherapy quality assurance: value, evolution and lessons.Clinical and translational radiation oncology · 2026Review
- Impact of tumour proximity to organs-at-risk in adaptive MR-guided SBRT for central lung tumours and metastases.Clinical and translational radiation oncology · 2026Article
- On the Use of 4D-PET/CT for the Safe SBRT Re-Irradiation of Central Lung Recurrence Within Radiation-Induced Fibrosis: A Clinical Case.Journal of clinical medicine · 2025Article
- Protocol of a phase II study to evaluate the efficacy and safety of deep-inspiration breath-hold daily online adaptive radiotherapy for centrally located lung tumours (PUDDING study).Radiation oncology (London, England) · 2024Article
- Stereotactic body radiotherapy in lung cancer: a contemporary review.Pathology oncology research : POR · 2024Review
- A human lung alveolus-on-a-chip model of acute radiation-induced lung injury.Nature communications · 2023Article
- Local control and survival after stereotactic body radiation therapy of early-stage lung cancer patients in Slovenia.Radiology and oncology · 2023Article
- Systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer.NPJ precision oncology · 2023Article
- Stereotactic body radiotherapy for pulmonary oligometastases: a monoinstitutional analysis of clinical outcomes and potential prognostic factors.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2022Article
- Dose-volume-based evaluation of convolutional neural network-based auto-segmentation of thoracic organs at risk.Physics and imaging in radiation oncology · 2022Article
- Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[European journal of nuclear medicine and molecular imaging · 2022Review
- Single-fraction stereotactic ablative body radiation therapy for primary and metastasic lung tumor: A new paradigm?World journal of clinical oncology · 2022Review
- Toxicity and efficacy of stereotactic body radiotherapy for ultra-central lung tumours: a single institution real life experience.The British journal of radiology · 2022Article
- Assessment of MRI-Linac Economics under the RO-APM.Journal of clinical medicine · 2021Article
- A multi-institutional analysis of fractionated versus single-fraction stereotactic body radiotherapy (SBRT) in the treatment of primary lung tumors: a comparison between two antipodal fractionations.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Article
- Dose coverage impacts local control in ultra-central lung oligometastases treated with stereotactic radiotherapy.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2021Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
14 authors.
Funding
Abstract
Evidence supports stereotactic body radiotherapy (SBRT) as a curative treatment option for inoperable early stage non-small-cell lung cancer (NSCLC) resulting in high rates of tumour control and low risk of toxicity. However, promising results are mainly derived from SBRT of peripheral pulmonary lesions, whereas SBRT for the central tumours can lead to severe radiation sequelae owing to the spatial proximity to the serial organs at risk. Robust data on the tolerance of mediastinal structures to high-dose hypofractionated radiation are limited; furthermore, there are many open questions regarding the efficiency, safety and response assessment of SBRT in inoperable, centrally located early stage NSCLC, which are addressed in a prospective multicentre study [sponsored by the European Organization for Research and Treatment of Cancer (EORTC 22113-08113-LungTech)]. In this review, we summarize the current status regarding SBRT for centrally located early stage NSCLC that leads to the rationale of the LungTech trial. Outline and some essential features of the study with focus on a summary of current experiences in dose/fraction-toxicity coherences after SBRT to the mediastinal structures that lead to LungTech normal tissue constraints are provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.